Cargando…

Glutamine, fatty liver disease and aging

Detalles Bibliográficos
Autores principales:	Simón, Jorge, Martínez-Chantar, María Luz, Delgado, Teresa C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906214/ https://www.ncbi.nlm.nih.gov/pubmed/33589573 http://dx.doi.org/10.18632/aging.202666

Ejemplares similares

Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease
por: Martínez-Chantar, María Luz, et al.
Publicado: (2021)

Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover
por: Simon, Jorge, et al.
Publicado: (2019)

Understanding gut-liver axis nitrogen metabolism in Fatty Liver Disease
por: Delgado, Teresa C., et al.
Publicado: (2022)

Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma
por: Delgado, Teresa Cardoso, et al.
Publicado: (2019)

Integrative Genomic Signatures Of Hepatocellular Carcinoma Derived from Nonalcoholic Fatty Liver Disease
por: Frades, Itziar, et al.
Publicado: (2015)

Nutraceutical Properties of Polyphenols against Liver Diseases
por: Simón, Jorge, et al.
Publicado: (2020)

Magnesium, Little Known But Possibly Relevant: A Link between NASH and Related Comorbidities
por: Simón, Jorge, et al.
Publicado: (2021)

Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis
por: Vegas-Suárez, Sergio, et al.
Publicado: (2022)

Diet and Lifestyle in Nonalcoholic Fatty Liver Disease
por: Martínez-Beamonte, Roberto, et al.
Publicado: (2020)

Magnesium and Liver Metabolism Through the Lifespan
por: Bravo, Miren, et al.
Publicado: (2023)

RB in glutamine metabolism
por: Clem, Brian
Publicado: (2014)

The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?
por: Iruzubieta, Paula, et al.
Publicado: (2015)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Liver osteopontin is required to prevent the progression of age‐related nonalcoholic fatty liver disease
por: Gómez‐Santos, Beatriz, et al.
Publicado: (2020)

Targeting glutamine uptake in AML
por: Jacque, Nathalie, et al.
Publicado: (2014)

Activated Fibroblasts: Gluttonous for Glutamine
por: Nieweld, Carl, et al.
Publicado: (2019)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Metabolic-associated Fatty Liver Disease
por: Zheng, Ming-Hua
Publicado: (2021)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Topical Effect of Glutamine for Colorectal Anastomosis
por: Kim, Jong-Woo
Publicado: (2015)

Glutamine Supplementation: The Pendulum Keeps on Swinging
por: Todi, Subhash
Publicado: (2019)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Effects of glutamine on oxidative stress and nuclear factor-κB expression in the livers of rats with nonalcoholic fatty liver disease
por: LIN, ZHIHUI, et al.
Publicado: (2014)

Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
por: Barbier-Torres, Lucía, et al.
Publicado: (2020)

Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
por: Han, Eugene
Publicado: (2022)

Fatty Liver Disease: Metabolic, Genetic, or Both?
por: Zoller, Heinz, et al.
Publicado: (2020)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

It’s Ready for Targeting Muscle in Nonalcoholic Fatty Liver in This Era of Aging
por: Joo, Sae Kyung, et al.
Publicado: (2019)

Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment
por: Martínez-Chantar, Maria L., et al.
Publicado: (2020)

Fatty liver in lean patients: is it a different disease?
por: Verdelho Machado, Mariana, et al.
Publicado: (2012)

Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
por: El Ouaamari, Abdelfattah, et al.
Publicado: (2013)

Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease
por: Kim, Sang Yong
Publicado: (2013)

Medicinal Herbs and Their Active Compounds for Fatty Liver Diseases
por: Son, Chang Gue, et al.
Publicado: (2017)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Treating Nonalcoholic Fatty Liver Disease From the Outside In?
por: Flynn, Charles R.
Publicado: (2019)

Imaging methods in the assessment of nonalcoholic fatty liver disease
por: Parente, Daniella Braz
Publicado: (2020)

β-cryptoxanthin and fatty liver disease: new insights
por: Clugston, Robin D.
Publicado: (2023)

It is time to expand the fatty liver disease community of practice
por: Lazarus, Jeffrey V., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g9677ocf91l2e6ecrlugjfl7gp